"In the third quarter, we delivered increased sequential earnings and stable CECL reserve and book values, while continuing to strengthen our financial flexibility by addressing risk rated 4 and 5 lo...

“Our third quarter results reflect another period of strong growth and financial progress,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies.